U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C21H25N.ClH
Molecular Weight 327.891
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TERBINAFINE HYDROCHLORIDE

SMILES

Cl.CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1

InChI

InChIKey=BWMISRWJRUSYEX-SZKNIZGXSA-N
InChI=1S/C21H25N.ClH/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19;/h5-7,9-14H,16-17H2,1-4H3;1H/b9-5+;

HIDE SMILES / InChI

Description

Terbinafine (brand name Lamisil, Terbisil, Terboderm and others) is an antifungal medication used to treat ringworm and fungal nail infections. Terbinafine inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell membrane synthesis pathway. Because terbinafine prevents the conversion of squalene to lanosterol, ergosterol cannot be synthesized. This is thought to change cell membrane permeability, causing fungal cell lysis. Many side effects and adverse drug reactions have been reported with oral terbinafine hydrochloride possibly due to its extensive biodistribution and the often extended durations involved in antifungal treatment (longer than two months).

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
30.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
LAMISIL

Cmax

ValueDoseCo-administeredAnalytePopulation
1.34 μg/mL
250 mg single, oral
TERBINAFINE plasma
Homo sapiens
1.7 μg/mL
250 mg 1 times / day multiple, oral
TERBINAFINE plasma
Homo sapiens
1 μg/mL
250 mg single, oral
TERBINAFINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4.74 μg × h/mL
250 mg single, oral
TERBINAFINE plasma
Homo sapiens
10.48 μg × h/mL
250 mg 1 times / day multiple, oral
TERBINAFINE plasma
Homo sapiens
4.56 μg × h/mL
250 mg single, oral
TERBINAFINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
16.5 day
250 mg 1 times / day multiple, oral
TERBINAFINE plasma
Homo sapiens
36 h
250 mg single, oral
TERBINAFINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
250 mg single, oral
TERBINAFINE plasma
Homo sapiens

Doses

AEs

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Prior to administering, evaluate patients for evidence of chronic or active liver disease. Fingernail onychomycosis: One 250 mg tablet, once daily for 6 weeks. Toenail onychomycosis: One 250 mg tablet, once daily for 12 weeks.
Route of Administration: Oral
In Vitro Use Guide
TRB (Terbinafine) were diluted 100-fold in dimethyl sulfoxide to obtain stock solutions that were kept at -20ºC. The antifungals were diluted in RPMI-1640 medium (Sigma Chemical Co, Missouri, USA) at pH 7.0 buffered with 0.16 M morpholinepropanesulfonic acid to obtain final concentrations ranging from 0.03-16 μg/mL for TRB. The diluted antifungal suspensions were then added to 96-well microtitre trays. Next, each fungal suspension was inoculated into the appropriate well at final concentrations ranging from 0.5 x 10^3-2.5 x 10^3 CFU/mL. The minimum inhibitory concentration (MIC) of each antifungal was determined by spectrophotometric reading at 492 nm following incubation at 35ºC for 72 h.